Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Public ClinicalTrials.gov record NCT01811212. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
Study identification
- NCT ID
- NCT01811212
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 25 participants
Conditions and interventions
Conditions
- Poorly Differentiated Thyroid Gland Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Stage I Thyroid Gland Follicular Carcinoma
- Stage I Thyroid Gland Papillary Carcinoma
- Stage II Thyroid Gland Follicular Carcinoma
- Stage II Thyroid Gland Papillary Carcinoma
- Stage III Thyroid Gland Follicular Carcinoma
- Stage III Thyroid Gland Papillary Carcinoma
- Stage IVA Thyroid Gland Follicular Carcinoma
- Stage IVA Thyroid Gland Papillary Carcinoma
- Stage IVB Thyroid Gland Follicular Carcinoma
- Stage IVB Thyroid Gland Papillary Carcinoma
- Stage IVC Thyroid Gland Follicular Carcinoma
- Stage IVC Thyroid Gland Papillary Carcinoma
- Tall Cell Variant Thyroid Gland Papillary Carcinoma
- Thyroid Gland Oncocytic Follicular Carcinoma
Interventions
- Cabozantinib S-malate Drug
- Laboratory Biomarker Analysis Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2013
- Primary completion
- Jul 12, 2015
- Completion
- Oct 8, 2017
- Last update posted
- Apr 2, 2018
2013 – 2017
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01811212, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2018 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01811212 live on ClinicalTrials.gov.